Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial
Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.read more...
Benzinga
More News
Clearmind Expands Its Addiction Therapy Playbook, as MEAI Could Open a New Path in Alcohol Use Disorder Treatment
Clearmind Medicine (NASDAQ:CMND) is advancing its lead therapeutic candidate, MEAI (5-Methoxy-2-aminoindane), with a successful formulation feasibility study supporting intranasal delivery as a potential additional route of administration. While still in development, the milestone reflects the company's broader strategy of enhancing the flexibility and commercial potential of its non-hallucinogenic neuroplastogen platform for treating alcohol use disorder (AUD), an area with substantial unmet medical need.
24-7 Market News
Biotech Stocks Are Loading Up on Major 2026 Catalysts and Wall Street Is Watching
Investors continue to focus on companies capable of generating meaningful clinical milestones, regulatory achievements, and commercial opportunities in large underserved markets. Several small-cap healthcare names now have potentially market-moving events scheduled throughout the remainder of 2026, positioning them among closely watched stocks in the biotech and healthcare sectors. $BCDA, $NTHI, $MTVA, $BGMS, $CMND
24-7 Market News
Why Did CMND Stock Jump 40% Today?
Clearmind Medicine announced that it filed a patent in Japan for its proprietary non-hallucinogenic psychedelic-based therapy for depression.
Stocktwits
Why Is Clearmind Medicine Stock Sliding On Wednesday?
Clearmind Medicine Inc. (NYSE: CMND) faces a price correction Wednesday following a massive rally. Read more on the impact of CMND-100 trial results and new executive orders.read more...
Benzinga
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.read more...
Benzinga
CMND Stock Set For Biggest Intraday Gains In Over Three Years — Here’s Why Retail Is Eyeing Further Upside
Psychedelic biotech stocks rallied after a new executive order fast-tracked drug approvals and funding.
Stocktwits
PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine
CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.
Stocktwits
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss? Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment...
PR Newswire
Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders
(RTTNews) - Clearmind Medicine (CMND) announced that it has entered into a development agreement with Polyrizon to create a proprietary intranasal formulation of MEAI, a non-hallucinogenic...
Nasdaq News: Markets

Advertisement|Remove ads.